Compile Data Set for Download or QSAR
Report error Found 30 Enz. Inhib. hit(s) with all data for entry = 50031433
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313179((R)-2-((S)-1-ethyl-3-methyl-4-(4-(trifluoromethyl)...)
Affinity DataIC50: 3nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313172((R)-2-((S)-1-ethyl-4-(4-ethylphenethyl)-3-methyl-6...)
Affinity DataIC50: 3nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313170(2-(1-ethyl-3-methyl-4-(4-methylphenethyl)-6,7-dihy...)
Affinity DataIC50: 6nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313178(2-(1-ethyl-3-methyl-4-(3-(trifluoromethyl)phenethy...)
Affinity DataIC50: 7nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313174((R)-2-((S)-1-ethyl-4-(4-isopropylphenethyl)-3-meth...)
Affinity DataIC50: 9nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313177(2-(1-ethyl-4-(3-fluorophenethyl)-3-methyl-6,7-dihy...)
Affinity DataIC50: 10nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313180(2-(4-(4-chlorophenethyl)-1-ethyl-3-methyl-6,7-dihy...)
Affinity DataIC50: 12nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313181((R)-2-((R)-1-ethyl-3-methyl-4-(p-tolyloxymethyl)-6...)
Affinity DataIC50: 19nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313169(2-(1-ethyl-3-methyl-4-(3-methylphenethyl)-6,7-dihy...)
Affinity DataIC50: 19nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313168(2-(1-ethyl-3-methyl-4-(2-methylphenethyl)-6,7-dihy...)
Affinity DataIC50: 21nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313176(2-(1-ethyl-4-(2-fluorophenethyl)-3-methyl-6,7-dihy...)
Affinity DataIC50: 22nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313182(2-(1-ethyl-3-methyl-4-(4-(trifluoromethyl)benzyl)-...)
Affinity DataIC50: 25nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313172((R)-2-((S)-1-ethyl-4-(4-ethylphenethyl)-3-methyl-6...)
Affinity DataIC50: 63nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313170(2-(1-ethyl-3-methyl-4-(4-methylphenethyl)-6,7-dihy...)
Affinity DataIC50: 108nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313179((R)-2-((S)-1-ethyl-3-methyl-4-(4-(trifluoromethyl)...)
Affinity DataIC50: 128nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313174((R)-2-((S)-1-ethyl-4-(4-isopropylphenethyl)-3-meth...)
Affinity DataIC50: 161nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313173((R)-2-((R)-1-ethyl-4-(4-ethylphenethyl)-3-methyl-6...)
Affinity DataIC50: 174nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313175((R)-2-((R)-1-ethyl-4-(4-isopropylphenethyl)-3-meth...)
Affinity DataIC50: 179nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313169(2-(1-ethyl-3-methyl-4-(3-methylphenethyl)-6,7-dihy...)
Affinity DataIC50: 180nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313171(2-(1-ethyl-4-(4-methoxyphenethyl)-3-methyl-6,7-dih...)
Affinity DataIC50: 219nMAssay Description:Antagonist activity at human OX2 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313178(2-(1-ethyl-3-methyl-4-(3-(trifluoromethyl)phenethy...)
Affinity DataIC50: 358nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313177(2-(1-ethyl-4-(3-fluorophenethyl)-3-methyl-6,7-dihy...)
Affinity DataIC50: 402nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313176(2-(1-ethyl-4-(2-fluorophenethyl)-3-methyl-6,7-dihy...)
Affinity DataIC50: 669nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313182(2-(1-ethyl-3-methyl-4-(4-(trifluoromethyl)benzyl)-...)
Affinity DataIC50: 769nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313180(2-(4-(4-chlorophenethyl)-1-ethyl-3-methyl-6,7-dihy...)
Affinity DataIC50: 993nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313168(2-(1-ethyl-3-methyl-4-(2-methylphenethyl)-6,7-dihy...)
Affinity DataIC50: 1.03E+3nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313173((R)-2-((R)-1-ethyl-4-(4-ethylphenethyl)-3-methyl-6...)
Affinity DataIC50: 1.42E+3nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313175((R)-2-((R)-1-ethyl-4-(4-isopropylphenethyl)-3-meth...)
Affinity DataIC50: 1.92E+3nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313171(2-(1-ethyl-4-(4-methoxyphenethyl)-3-methyl-6,7-dih...)
Affinity DataIC50: 1.00E+4nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50313181((R)-2-((R)-1-ethyl-3-methyl-4-(p-tolyloxymethyl)-6...)
Affinity DataIC50: 1.00E+4nMAssay Description:Antagonist activity at human OX1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/18/2010
Entry Details Article
PubMed